We present an unusual case of post-transplant lymphoproliferative disorder (PTLD) presenting as apparently isolated gastrointestinal lesions in a pediatric renal transplant recipient. The multiple bowel lesions were related to Epstein-Barr virus and demonstrated the appearance of a monomorphic PTLD that was morphologically indistinguishable from diffuse large B-cell lymphoma. The patient responded to therapy with targeted anti-CD20 immunotherapy. PTLD may manifest as apparently isolated gastrointestinal tract lesions in childhood.
HarrisNL, SwerdlowSH, FrizzeraG, KnowlesDM. Post-transplant lymphoproliferative disorders. In: JaffeES, HarrisNL, SteinH, VardimanJW, eds. Tumours of Haematopoietic and Lymphoid Tissues; Pathology and Genetics. Lyon: IARC Press. 2001; p 264–269.
2.
CaillardS, LachatV, MoulinB.Posttransplant lymphoproliferative disorders in renal allograft recipients: report of 53 cases of a French multicenter study. PTLD French Working Group. Transpl Int2000;13(suppl 3):88–93.
3.
DharnidharkaVR, SullivanEK, StableinDM, TejaniAH, HarmonWE, for the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS). Risk factors for posttransplant lymphoproliferative disorder (PTLD) in pediatric kidney transplantation: a report of the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS). Transplantation2001;71:1065–1068.
4.
EBPG Expert Group on Renal Transplantation.European best practice guidelines for renal transplantation. Section IV: long-term management of the transplant recipient. IV. 6.1. Cancer risk after renal transplantation. Post-transplant lymphoproliferative disease (PTLD): prevention and treatment. Nephrol Dial Transpl 2002;17:35–36.
5.
IfthikharuddinJJ, MielesLA, RosenblattJD, RyanCK, SahasrabudheDM. CD-20 expression in post-transplant lymphoproliferative disorders: treatment with rituximab. Am J Hematol2000;65:171–173.
6.
HachemRR, ChakinalaMM, YusenRD, LynchJP, AloushAA, PattersonGA, TrulockEP. Abdominal-pelvic lymphoproliferative disease after lung transplantation: presentation and outcome. Transplantation2004;77:431–437.
7.
PickhardtPJ, SiegelMJ. Posttransplantation lymphoproliferative disorder of the abdomen: CT evaluation in 51 patients. Radiology1999;213:73–78.
8.
SwinnenLJ. Diagnosis and treatment of transplant-related lymphoma. Ann Oncol2000;11:45–48.
9.
RamalingamP, ChuWS, TubbsR, RybickiL, PettayJ, HsiED. Latent membrane protein 1, tumor necrosis factor receptor-associated factor (TRAF) 1, TRAF-2, TRAF-3, and nuclear factor kappa B expression in posttransplantation lymphoproliferative disorders. Arch Pathol Lab Med2003;127:1335–1339.
10.
PinkertonCR, HannI, WestonCL, MappT, WotherspoonA, HobsonR, KellyDA, VerganiD, HadzicD, ReesL, BurkeM, Alero ThomasJ.Immunodeficiency-related lymphoproliferative disorders: prospective data from the Registry. Br J Haematol2002;118:456–461.
11.
GulleyML, SwinnenLJ, PlaisanceKTJr, SchnellC, GroganTM, SchneiderBG. Tumor origin and CD20 expression in posttransplant lymphoproliferative disorder occurring in solid organ transplant recipients: implications for immune-based therapy. Transplantation2003;76:959–964.
